Upadhyay Aditya, Jaiswal Neha, Kumar Awanish
Department of Biotechnology, National Institute of Technology, Raipur, 492010, (CG), India.
Department of Biotechnology, National Institute of Technology, Raipur, 492010, (CG), India.
Microb Pathog. 2025 Feb;199:107277. doi: 10.1016/j.micpath.2025.107277. Epub 2025 Jan 3.
Bacterial biofilm infections are the root cause of persistent infections and the prevalence of resistance to specific or multiple antibiotics. Biofilms have unique features that provide a protective environment for bacteria under various stress conditions and contribute significantly to the pathogenesis of chronic infections. They cover bacterial cells with a self-produced extracellular polymeric matrix, effectively hiding the bacterial cells and their targets. Conventional therapies cannot effectively treat and control bacterial biofilm infections. Therefore, advanced therapeutic means like microneedles, targeted tissue therapy, phage therapy, nanodrug therapy, combination drug therapy, microbial therapy, and immune cell hijacking therapy are needed to tackle the complex issue. These advanced therapies have shown promising results not only in bacterial biofilm infections but also in diseases such as cancer and genetic disorders. Due to their unique features and mechanisms, they significantly contribute to preventing bacterial infections by disrupting biofilm. This article aims to serve as a comprehensive overview of the ongoing battle against biofilms with transformative therapies. This article compiles advancements in new therapies that have demonstrated effective roles in the disruption of bacterial biofilms. We also discuss the current developments and Food and Drug Administration-approved status of these therapies. Additionally, this article summarizes the limitations and future steps needed for these therapies in the field of bacterial biofilm prevention. Thus, these therapies represent the future of preventing bacterial biofilm infections and could be also effective in the reversal of resistance.
细菌生物膜感染是持续性感染以及对特定或多种抗生素产生耐药性的根本原因。生物膜具有独特的特性,能在各种应激条件下为细菌提供一个保护环境,并在慢性感染的发病机制中发挥重要作用。它们用自身产生的细胞外聚合物基质覆盖细菌细胞,有效地隐藏细菌细胞及其靶点。传统疗法无法有效治疗和控制细菌生物膜感染。因此,需要诸如微针、靶向组织疗法、噬菌体疗法、纳米药物疗法、联合药物疗法、微生物疗法和免疫细胞劫持疗法等先进的治疗手段来解决这一复杂问题。这些先进疗法不仅在细菌生物膜感染方面显示出有前景的结果,而且在癌症和遗传疾病等病症中也有成效。由于其独特的特性和机制,它们通过破坏生物膜对预防细菌感染有显著贡献。本文旨在全面概述利用变革性疗法对抗生物膜的持续斗争。本文汇编了在破坏细菌生物膜方面已显示出有效作用的新疗法的进展。我们还讨论了这些疗法的当前发展情况以及美国食品药品监督管理局的批准状态。此外,本文总结了这些疗法在细菌生物膜预防领域的局限性以及未来所需采取的步骤。因此,这些疗法代表了预防细菌生物膜感染的未来,并且在逆转耐药性方面也可能有效。